Evidence map›Paper›PMID 42582463›Full record

ArticleBrain communications2026

Posterior cortical atrophy and logopenic variant primary progressive aphasia are more specific for Alzheimer's disease pathology than probable Alzheimer's disease.

Lydia Trudel, Joseph Therriault, Arthur C Macedo, Nesrine Rahmouni, Jean-Paul Soucy, Serge Gauthier, Paolo Vitali, Marie-Christine Guiot, Lili-Naz Hazrati, Pedro Rosa-Neto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lydia TrudelTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.ORCID https://orcid.org/0009-0002-5593-7717
Joseph TherriaultTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.
Arthur C MacedoTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.
Jean-Paul SoucyTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.
Serge GauthierTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.
Paolo VitaliTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.ORCID https://orcid.org/0000-0001-8953-1542
Marie-Christine GuiotDepartment of Neuropathology, Montreal Neurological Institute, McGill University, Montreal, QC H3A 1A1, Canada.
Lili-Naz HazratiDepartment of Neuropathology, Montreal Neurological Institute, McGill University, Montreal, QC H3A 1A1, Canada.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, QC H3A 1A1, Canada.ORCID https://orcid.org/0000-0001-9116-1376

Funding

National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BRADFORD C DICKERSON · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS R01 AG079280NIA NIH HHS U24 AG072122
6 · The paper itself

Abstract

Accurately diagnosing Alzheimer's disease is challenging, as 15-30% of individuals diagnosed clinically lack evidence of Alzheimer's disease neuropathological changes (ADNC) at autopsy. While the typical amnestic presentation of Alzheimer's disease may have limited specificity due to coexisting age-related pathologies, atypical presentations such as logopenic variant primary progressive aphasia (lvPPA) or posterior cortical atrophy (PCA) are often associated with ADNC. This study evaluated how well clinical diagnoses of amnestic and atypical Alzheimer's disease predict ADNC and how co-pathologies contribute to clinical-pathological discordance. To evaluate how clinical diagnosis predicts ADNC, we calculated positive predictive values (PPVs) and negative predictive values (NPVs) for clinical diagnoses of PCA, lvPPA, amnestic Alzheimer's disease or non-Alzheimer's disease dementia for ADNC, using four neuropathological thresholds defined by combinations of the Consortium to Establish a Registry for Alzheimer's disease (CERAD) neuritic plaque frequency (moderate or frequent) and Braak stage (III-VI or V-VI). Analyses were replicated

Indexed as

Alzheimer’s disease neuropathologic change (ADNC)atypical Alzheimer’s diseaseclinical-pathological correlationlogopenic primary progressive aphasia (lvPPA)posterior cortical atrophy (PCA)

Identifiers

PMID42582463
PMCPMC13457939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.